Study reveals alarming failures in the detection of pancreatic cancer

Pancreatic cancer
Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain

Pancreatic cancer tumors are being missed on CT and MRI scans, narrowing the window for life-saving curative surgery, research presented today at UEG Week 2022 has revealed.

The study analyzed post-imaging pancreatic cancer (PIPC) cases, where a patient undergoes imaging that fails to diagnose pancreatic cancer but is then later diagnosed with the disease. Results revealed over a third (36%) of PIPC cases were potentially avoidable, demonstrating a poor detection rate for a cancer that has alarming .

UK researchers studied the records of 600 patients diagnosed with pancreatic cancer between 2016 and 2021. Of those, 46 (7.7%) patients failed to have their cancer diagnosed through their first scan, but then received a pancreatic cancer diagnosis between 3 and 18 months later.

CT and MRI images were independently reviewed by radiologists to develop an algorithm to categorize the missed cases and identify the most likely explanation for why they were missed.

Dr. Nosheen Umar, the lead author of the study, from the University of Birmingham, UK, commented, “There is often only a very short period for curative surgery in pancreatic cancer, meaning it is vital that patients are diagnosed with the disease as early as possible to give them the best chance of survival. The study found that evidence of pancreatic cancer was initially missed in over a third of patients with post-imaging pancreatic cancers, which is a huge window of lost opportunity.”

In almost half (48%) of PIPC patients examined, there were signs of cancer that had been missed when scans were reviewed by a specialist hepatobiliary radiologist. In 28% of PIPC patients, imaging signs associated with pancreatic cancer, such as dilated bile or pancreatic ducts, were not recognized and investigated further.

“We hope this study will raise awareness of the issue of post-imaging pancreatic cancer and common reasons why pancreatic cancer can be initially missed,” explained Dr. Umar. “This will help to standardize future studies of this issue and guide quality improvement efforts, so we can increase the likelihood of an early diagnosis of pancreatic cancer, increase the chances of patient survival, and ultimately, save lives.”

Responsible for 95,000 deaths in the EU every year, pancreatic cancer has the lowest survival rate of all cancers in Europe and life expectancy at the time of diagnosis is just 4.6 months. By 2035, the number of cases of is predicted to rise by almost 40%.

Many patients are diagnosed at a late stage because the disease often presents vague early symptoms, making early recognition challenging. Symptoms can include jaundice, abdominal and back pain, unexplained weight loss and nausea. The complex nature of the disease also makes screening for early diagnosis challenging to implement.

Provided byUnited European Gastroenterology

Citation: Study reveals alarming failures in the detection of pancreatic cancer (2022, October 10) retrieved 6 November 2022 from https://medicalxpress.com/news/2022-10-reveals-alarming-failures-pancreatic-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Heike Prinz appointed to Board of Management of Bayer AG thumbnail

Heike Prinz appointed to Board of Management of Bayer AG

Leverkusen, August 21, 2023 – The Supervisory Board of Bayer AG has unanimously appointed Heike Prinz to Bayer’s Board of Management effective September 1, 2023. She will become the company’s Chief Talent Officer and Labor Director. This follows the mutual agreement by Board member Sarena Lin and Bayer’s Supervisory Board to not extend her contract
Read More
Cantik Saja Tak Cukup, Maria Andromeda: Miss Indonesia Harus Punya Nilai Plus thumbnail

Cantik Saja Tak Cukup, Maria Andromeda: Miss Indonesia Harus Punya Nilai Plus

SEBAGAI Finalis Miss Indonesia 2017, Maria Andromeda menilai Miss Indonesia bukanlah sekedar ajang pamer kecantikan. Maria Andromeda paham betul mengenai apa saja yang dibutuhkan wanita Indonesia jika ingin menjajakan kaki di ajang Miss Indonesia.  Hal itu membuat ajang Miss Indonesia begitu spesial di mata finalis yang menyabet kategori Miss Persahabatan kala itu. Bagi Maria, perempuan…
Read More
Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer thumbnail

Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer

Meeting Coverage > IGCS — Overall response beats historical benchmark, but misses significance target by Mike Bassett, Staff Writer, MedPage Today November 6, 2023 SEOUL, South Korea -- Combining the novel anti-TIGIT monoclonal antibody tiragolumab with atezolizumab (Tecentriq) to treat PD-L1-positive recurrent cervical cancer didn't improve overall response rate (ORR) in the phase II SKYSCRAPER-04
Read More
Alabama Leading US in COVID-19 Death Rate Over Last Week thumbnail

Alabama Leading US in COVID-19 Death Rate Over Last Week

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. MONTGOMERY, Ala. (AP) — Alabama has averaged more than 100 deaths a day from COVID-19 over the last week, statistics showed Thursday, giving it the nation's highest death rate over the period even as hospitalizations linked to the coronavirus pandemic continue…
Read More
Index Of News
Total
0
Share